NHS Rolls Out 60-Second Cancer Immunotherapy Jab That Could Transform Treatment for Thousands
The NHS has begun rolling out a revolutionary new cancer treatment that can be administered in a single injection in as little as 60 seconds, a development that promises to transform the treatment experience for tens of thousands of patients. The new injectable form of the immunotherapy drug pembrolizumab (also known as Keytruda) will drastically cut treatment times, which currently can take up to an hour per session via intravenous infusion.
Background
Immunotherapy is one of the most significant advances in cancer treatment in recent decades. It works by harnessing the body's own immune system to fight cancer cells. Pembrolizumab is a type of immunotherapy called a 'checkpoint inhibitor' that has proven effective in treating a wide range of cancers, including lung, kidney, bladder, and head and neck cancers, as well as melanoma. Traditionally, these drugs are administered intravenously (IV) in a hospital setting, a process that requires a cannula to be inserted into a vein and the drug to be slowly infused, often taking between 30 and 60 minutes per session.
Key Developments
Following successful trials and approval by the Medicines and Healthcare products Regulatory Agency (MHRA), NHS England has now made the new subcutaneous (under the skin) injection of pembrolizumab available to patients. This new formulation allows the same dose of the drug to be administered via a simple injection into the thigh, a process that takes around 60 seconds. This represents a reduction in treatment time of up to 90%. The NHS estimates that tens of thousands of patients with over a dozen different types of cancer will be eligible to switch from the IV infusion to the faster jab, freeing up huge amounts of time for both patients and specialist cancer nurses. Source: NHS England News.
Why It Matters
This innovation is a game-changer for cancer care. For patients, who may have to undergo treatment every few weeks for months or even years, the time saving is immense. It means less time spent in hospital, reduced travel, and a less invasive treatment experience, all of which significantly improves their quality of life. For the NHS, the benefits are equally profound. Each switch from an infusion to an injection frees up a slot in a chemotherapy day unit and saves valuable time for highly trained cancer nurses, who can then care for more patients or focus on more complex cases. It is a simple change that makes the entire system more efficient, allowing the NHS to treat more people, more quickly.
Local Impact
This is a development that will be of huge interest to cancer patients and healthcare providers in Northern Ireland. While the rollout is currently for NHS England, new treatments and formulations approved for use there are typically adopted in Northern Ireland shortly after. The introduction of the 60-second immunotherapy jab in cancer centres in Belfast and across the province would bring the same benefits to local patients. It would reduce the burden of treatment for thousands of people and help to alleviate pressure on busy chemotherapy units, which are facing rising demand. Local health officials will be watching the English rollout closely to plan for its implementation here.
What's Next
The rollout of the injectable pembrolizumab will continue across NHS England over the coming months. It is part of a wider NHS strategy to deliver more cancer care in more convenient ways, including in patients' homes where appropriate. The success of this initiative is likely to accelerate the development of injectable formulations for other immunotherapy drugs and chemotherapies. This shift away from time-consuming infusions towards quick and simple injections represents a significant step forward in making cancer treatment more manageable and patient-friendly. Read more about this innovation on the NHS website.
